NO20014876L - Lav-molekyl¶re inhibitorer av komplement-proteaser - Google Patents

Lav-molekyl¶re inhibitorer av komplement-proteaser

Info

Publication number
NO20014876L
NO20014876L NO20014876A NO20014876A NO20014876L NO 20014876 L NO20014876 L NO 20014876L NO 20014876 A NO20014876 A NO 20014876A NO 20014876 A NO20014876 A NO 20014876A NO 20014876 L NO20014876 L NO 20014876L
Authority
NO
Norway
Prior art keywords
molecular
low
weight inhibitors
complement proteases
complement
Prior art date
Application number
NO20014876A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014876D0 (no
Inventor
Heinz Hillen
Martin Schmidt
Helmut Mack
Werner Seitz
Andreas Haupt
Johann-Christian Zechel
Andreas Kling
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20014876D0 publication Critical patent/NO20014876D0/no
Publication of NO20014876L publication Critical patent/NO20014876L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
NO20014876A 1999-04-09 2001-10-08 Lav-molekyl¶re inhibitorer av komplement-proteaser NO20014876L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19915930 1999-04-09
PCT/EP2000/002710 WO2000061608A2 (de) 1999-04-09 2000-03-28 Niedermolekulare inhibitoren von komplementproteasen

Publications (2)

Publication Number Publication Date
NO20014876D0 NO20014876D0 (no) 2001-10-08
NO20014876L true NO20014876L (no) 2001-12-04

Family

ID=7903946

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014876A NO20014876L (no) 1999-04-09 2001-10-08 Lav-molekyl¶re inhibitorer av komplement-proteaser

Country Status (22)

Country Link
US (1) US6683055B1 (hu)
EP (1) EP1169338B1 (hu)
JP (1) JP4489976B2 (hu)
KR (1) KR20010108477A (hu)
CN (1) CN1351609A (hu)
AT (1) ATE281466T1 (hu)
AU (1) AU4111700A (hu)
BG (1) BG105978A (hu)
BR (1) BR0009678A (hu)
CA (1) CA2369378A1 (hu)
CZ (1) CZ20013577A3 (hu)
DE (1) DE50008510D1 (hu)
HK (1) HK1045846A1 (hu)
HU (1) HUP0203167A3 (hu)
IL (1) IL145771A0 (hu)
MX (1) MXPA01010114A (hu)
NO (1) NO20014876L (hu)
PL (1) PL351441A1 (hu)
SK (1) SK14232001A3 (hu)
TR (1) TR200102913T2 (hu)
WO (1) WO2000061608A2 (hu)
ZA (2) ZA200107890B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144902B1 (en) * 1999-04-09 2006-12-05 Abbott Gmbh & Co. Kg Prodrugs of thrombin inhibitors
NZ547626A (en) * 2000-08-11 2007-10-26 Wilex Ag Non-covalent inhibitors of urokinase and blood vessel formation
EP1182207B1 (en) * 2000-08-11 2007-04-18 Dendreon Corporation Non-covalent inhibitors of urokinase and blood vessel formation
AU2003206945A1 (en) * 2002-02-22 2003-09-09 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of proteinase inhibitors in the treatment of autoimmune diseases
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
JP4459629B2 (ja) 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
ES2522525T3 (es) * 2003-05-15 2014-11-14 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
TW200519105A (en) * 2003-10-20 2005-06-16 Lg Life Science Ltd Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
CN1304568C (zh) * 2004-07-05 2007-03-14 中国人民解放军第二军医大学 新型人补体C1r样丝氨酸蛋白酶类似物,其编码序列及用途
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8221804B2 (en) * 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
KR20080002832A (ko) * 2005-03-16 2008-01-04 얀센 파마슈티카 엔.브이. 보체 매개성 질병 및 이상을 치료하기 위한 신규한 티오펜설폭시민
JP5607025B2 (ja) 2008-04-21 2014-10-15 シグナム バイオサイエンシーズ， インコーポレイテッド 化合物、組成物およびそれらを作製する方法
CN102464701B (zh) * 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
IN2014CN02805A (hu) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
TWI633091B (zh) 2011-10-14 2018-08-21 Bristol-Myers Squibb Company 作為因子ｘｉａ抑制劑之經取代四氫異喹啉化合物
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
NZ707990A (en) 2012-10-12 2018-07-27 Bristol Myers Squibb Co Crystalline forms of a factor xia inhibitor
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
NO2760821T3 (hu) 2014-01-31 2018-03-10
DK3099687T3 (en) 2014-01-31 2018-10-22 Bristol Myers Squibb Co MACROCYCLES WITH HETEROCYCLIC P2 'GROUPS AS FACTOR XIA INHIBITORS
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP2022519924A (ja) * 2019-03-22 2022-03-25 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体媒介性障害の治療のための医薬化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738910A1 (de) 1987-11-17 1989-05-24 Basf Ag Tributylammoniumsalz von 1,1-dicyano-2-hydroxy-3-chlorprop-1-en, ein verfahren zu seiner herstellung sowie ein verfahren zur herstellung von 2-amino-4-chlor-3-cyano-5-formylthiophen
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
DE4443390A1 (de) * 1994-12-06 1996-06-13 Basf Ag Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
KR19980702112A (ko) * 1995-02-10 1998-07-15 페라 스타르크,요헨 카르크 트롬빈 억제제
SI9620037A (sl) 1995-02-17 1998-02-28 Basf Aktiengesellschaft Novi trombinski inhibitorji
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
DE19632772A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
DE19632773A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Thrombininhibitoren
DE19635674A1 (de) 1996-09-03 1998-03-05 Basf Ag Verfahren zur Herstellung von Amidinen
US6653340B1 (en) * 1997-06-03 2003-11-25 Biocryst Pharmaceuticals, Inc. Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
WO1999037668A1 (de) * 1998-01-26 1999-07-29 Basf Aktiengesellschaft Thrombininhibitoren
WO1999037611A1 (de) * 1998-01-26 1999-07-29 Basf Aktiengesellschaft Heterocyclische amidine als kallikrein protease inhibitoren

Also Published As

Publication number Publication date
CA2369378A1 (en) 2000-10-19
CZ20013577A3 (cs) 2002-07-17
ATE281466T1 (de) 2004-11-15
NO20014876D0 (no) 2001-10-08
PL351441A1 (en) 2003-04-22
ZA200107978B (en) 2003-03-26
IL145771A0 (en) 2002-07-25
SK14232001A3 (sk) 2002-06-04
JP4489976B2 (ja) 2010-06-23
EP1169338A2 (de) 2002-01-09
MXPA01010114A (es) 2002-07-30
HUP0203167A3 (en) 2003-09-29
HK1045846A1 (zh) 2002-12-13
DE50008510D1 (de) 2004-12-09
CN1351609A (zh) 2002-05-29
TR200102913T2 (tr) 2002-01-21
AU4111700A (en) 2000-11-14
ZA200107890B (en) 2003-11-26
US6683055B1 (en) 2004-01-27
WO2000061608A2 (de) 2000-10-19
KR20010108477A (ko) 2001-12-07
BG105978A (bg) 2002-07-31
BR0009678A (pt) 2002-01-22
HUP0203167A2 (hu) 2003-02-28
EP1169338B1 (de) 2004-11-03
WO2000061608A3 (de) 2001-01-11
JP2002542164A (ja) 2002-12-10

Similar Documents

Publication Publication Date Title
NO20014876L (no) Lav-molekyl¶re inhibitorer av komplement-proteaser
WO2000076971A3 (en) Serine protease inhibitors
FI955315A0 (fi) HIV:n proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDS'n hoitoon
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
TR200103216T2 (tr) Pirimidinon bileşimleri
DK1265971T3 (da) Bioadhæsiv komposition, der omfatter et polyphenolprotein
ATE330017T1 (de) Kallikrein gen
DE60028276D1 (de) Verringerung von Verzögerung in Mehrträgerempfängern
NO20013853L (no) Heteroarylamidiner, metylamidiner og guanidiner som proteaseinhibitorer
WO2002043706A3 (en) Prolamin-based sustained-release compositions and delayed-onset compositions
TR200401363T4 (tr) DNA viral enfeksiyonlarının tedavisi
BR9911373A (pt) Inibidores de triptase de amidino e guanidino azetidinona
FR2833599B1 (fr) Polysaccharide amphotere, composition et utilisation
DK1244643T3 (da) Tryptaseinhibitorer
DE60011300D1 (de) Inhibitoren der tryptase
TR199802703T2 (xx) HIV tedavisinde Vx478, Zidov�din, ve/veya 1592U89 i�eren kombinasyonlar�n kullan�m�.
TR200103662T2 (tr) Yeni kalpainler ve bunların kullanılması
NO993699L (no) Håndtering av objekter i telekommunikasjonssystemer
AU2002231643A1 (en) Light arrangement comprising at least two edge rails lying opposite each other
AU7361000A (en) Epithelial protein lost in neoplasm (eplin)
WO1998055506A3 (de) Thrombin hemmende peptide
DE69937998D1 (de) Antiproliferative und antivirale proteine und peptide
ES1043975Y (es) Plegado de mesa y banco.
TH48056A3 (th) สารผสมดูแลสำหรับการดูแลส่วนตัวที่มีเอนไซม์ สับทิลิซิน ที่ถูกจับยึดไว้กับซับสเตรทที่ไม่ละลายในน้ำ
IT1313362B1 (it) Cella di elettrodialisi,elettrodializzatore e impiego di dettoelettrodializzatore.